Pathognomonic and epistatic genetic alterations in

1 2

B-cell non-Hodgkin lymphoma

3

Man Chun John Ma^{1*}, Saber Tadros^{1*}, Alyssa Bouska², Tayla B. Heavican², Haopeng Yang¹,
Qing Deng¹, Dalia Moore³, Ariz Akhter⁴, Keenan Hartert³, Neeraj Jain¹, Jordan Showell¹,
Sreejoyee Ghosh¹, Lesley Street⁵, Marta Davidson⁵, Christopher Carey⁶, Joshua Tobin⁷,
Deepak Perumal⁸, Julie M. Vose⁹, Matthew A. Lunning⁹, Aliyah R. Sohani¹⁰, Benjamin J.
Chen¹¹, Shannon Buckley¹², Loretta J. Nastoupil¹, R. Eric Davis¹, Jason R. Westin¹, Nathan H.
Fowler¹, Samir Parekh⁸, Maher K. Gandhi⁷, Sattva S. Neelapu¹, Douglas Stewart⁵, Javeed
Iqbal², Timothy Greiner², Scott J. Rodig¹³, Adnan Mansoor⁵, Michael R. Green^{1,14,15*}

11 ¹Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD 12 Anderson Cancer Center, Houston, TX, USA; ²Department of Pathology and Microbiology, University of 13 Nebraska Medical Center, Omaha, NE, USA; ³Eppley Institute for Research in Cancer and Allied 14 Diseases, University of Nebraska Medical Center, Omaha, NE, USA; ⁴Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; ⁵Section of Hematology, Department of 15 Medicine, University of Calgary, Calgary, AB, Canada; ⁶Northern Institute for Research, Newcastle 16 17 University, Newcastle upon Tyne, England; ⁷Mater Research, University of Queensland, QLD, Australia; ⁸Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 18 USA; ⁹Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska 19 Medical Center, Omaha, NE, USA; ¹⁰Department of Pathology, Massachusetts General Hospital and 20 Harvard Medical School, Boston, MA, USA; ¹¹Department of Pathology, University of Massachusetts 21 Medical School, UMass Memorial Medical Center, Worcester, MA, USA; ¹²Department of Genetics, Cell 22 Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA; ¹³Department of Pathology, Brigham and Womens Hospital, Boston, MA, USA; ¹⁴Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁵Center for Cancer Epigenetics, 23 24 25 26 University of Texas MD Anderson Cancer Center, Houston, TX, USA.

- 27 [¥]Equally contributed
- 28 *Corresponding Author
- 29 Michael R. Green, Ph.D.
- 30 Departments of Lymphoma/Myeloma and Genomic Medicine,
- 31 University of Texas MD Anderson Cancer Center,
- 32 1515 Holcombe Blvd, Unit 903,
- Houston, TX 77030, USA
- 34 Ph.: +1-713-745-4244
- 35 Email: mgreen5@mdanderson.org

36

37

38

39 KEY POINTS

Genetic perturbation of the ubiquitin proteasome system is an emerging hallmark of B cell non-Hodgkin lymphoma (B-NHL).

42 2. Co-occurring sets of genetic alterations define B-NHL subtypes and likely represent

43 epistatic interactions.

44

45 ABSTRACT

B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically 46 47 distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL 48 such as diffuse large B-cell lymphoma (DLBCL) have been comprehensively interrogated at the genomic level, but other less common subtypes such as mantle cell lymphoma (MCL) remain 49 50 sparsely characterized. Furthermore, multiple B-NHL subtypes have thus far not been 51 comprehensively compared to identify conserved or subtype-specific patterns of genomic 52 alterations. Here, we employed a large targeted hybrid-capture sequencing approach 53 encompassing 380 genes to interrogate the genomic landscapes of 755 B-NHL tumors at high depth; primarily including DLBCL, MCL, follicular lymphoma (FL), and Burkitt lymphoma (BL). 54 55 We identified conserved hallmarks of B-NHL that were deregulated across major subtypes, such 56 as the frequent genetic deregulation of the ubiquitin proteasome system (UPS). In addition, we 57 identified subtype-specific patterns of genetic alterations, including clusters of co-occurring 58 mutations that are pathognomonic. The cumulative burden of mutations within a single cluster 59 were more significantly discriminatory of B-NHL subtypes than individual mutations, implicating 60 likely patterns of genetic epistasis that contribute to disease etiology. We therefore provide a 61 framework of co-occurring mutations that deregulate genetic hallmarks and likely cooperate in 62 lymphomagenesis of B-NHL subtypes.

63 INTRODUCTION

64 Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoid malignancies that 65 predominantly arise from mature B-cells (B-NHL). Although mature B-cell neoplasms encompass 38 unique diagnostic subtypes, over 85% of cases fall within only 7 subtypes^{1,2}. 66 67 Recent next generation sequencing (NGS) studies have shed light onto the key driver mutations in many of these NHL subtypes; for example, large studies of diffuse large B-cell lymphoma 68 (DLBCL) have led to proposed genomic subtypes that have unique etiologies³⁻⁵. However, many 69 70 less-common NHL subtypes such as mantle cell lymphoma (MCL) have not been as extensively characterized^{6,7}. Furthermore, until recently^{3,4} genetic alterations have been considered in a 71 72 binary fashion as either driver events, which directly promote disease genesis or progression, or passenger events, which have little or no impact on disease biology. In contrast to this principle, 73 74 most B-NHLs do not result from a single dominant driver but instead result from the serial 75 acquisition of genetic alterations that cooperate in lymphomagenesis. The genetic context of 76 each mutation therefore likely determines its oncogenic potential, and groups of mutations 77 should therefore be considered collectively rather than as singular events. For example, the 'C5' and 'MCD' clusters identified in DLBCL by Chapuy et al. and Schmitz et al., respectively, are 78 characterized by the co-occurrence of *CD79B* and *MYD88* mutations^{3,4}. In animal models, the 79 80 Myd88 L265P mutation was found to promote down-regulation of surface IgM and a phenotype resembling B-cell anergy⁸. However, this effect could be rescued by *Cd79b* mutation, showing 81 that these co-occurring mutations are epistatic⁸. The characterization of other significantly co-82 83 occurring genetic alterations are therefore likely to reveal additional important epistatic relationships. 84

85

We approached this challenge by performing genomic profiling of 755 B-NHLs across different subtypes. Through this cross-sectional analysis we characterized genomic hallmarks of B-NHL and identified pathognomonic genetic alterations, including disease-specific mechanisms for deregulating hallmark processes and protein complexes, and sets of significantly co-associated events that represent subtype-specific epistatic genetic alterations. This study therefore provides new insight into how cooperating genetic alterations may contribute to molecularly and phenotypically distinct subtypes of B-NHL.

93

94 METHODS

An overview of our approach is shown in Figure S1. For detailed methods, please refer to
 supplementary information.

97

98 <u>Tumor DNA samples</u>

99 We collected DNA for 755 B-NHL tumors, including 199 follicular lymphoma (FL), 196 mantle 100 cell lymphoma (MCL), 148 diffuse large B-cell lymphoma (DLBCL), 108 Burkitt's lymphoma 101 (BL), 45 chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), 24 marginal 102 zone lymphoma (MZL), 21 high-grade B-cell lymphoma not otherwise specified (HGBL-NOS), 103 and 14 high-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangement (DHL) (Table 104 S1). A total of 502 samples were obtained from the University of Nebraska Medical Center, and were prioritized for inclusion in this study if they had fresh/frozen tissue available (n=577) and 105 106 been previously interrogated by Affymetrix U133 Plus 2.0 gene expression microarrays (n=290)⁹⁻¹¹. An additional series of 178 formalin-fixed paraffin-embedded (FFPE) tumors were 107 collected from other centers. Samples were de-identified but accompanied by their diagnosis 108 109 from medical records, plus overall survival time and status (alive, dead) when available. Medical 110 record diagnosis was used in all cases except for those with fluorescence in situ hybridization 111 showing translocations in MYC and BCL2 and/or BCL6, which were amended to DHL.

Sequencing results for a subset of 52 BL tumors was described previously¹². All MCL samples were either positive for *CCND1* translocation by FISH or positive for CCND1 protein expression by IHC, depending on the diagnostic practices of the contributing institution.

115

116 Next generation sequencing

117 A total of 100-1000ng of gDNA was sonicated using a Covaris S2 Ultrasonicator, and libraries 118 prepared using KAPA Hyper Prep Kits (Roche) with TruSeq Adapters (Bioo Scientific) and a 119 maximum of 8 cycles of PCR (average of 6 cycles). Libraries were gualified by TapeStation 4200, guantified by Qubit and 10- to 12-plexed for hybrid capture. Each multiplexed library was 120 121 enriched using our custom LymphoSeg panel encompassing the full coding sequences of 380 genes that have previously been reported to be somatically mutated in B-cell lymphoma^{6,7,13-32} 122 123 (Table S2, Supplementary Methods), as well as tiling recurrent translocation breakpoints. 124 Enrichments were amplified with 4-8 cycles of PCR and sequenced on a single lane of an 125 Illumina HiSeq 4000 with 100PE reads in high-output mode at the Hudson Alpha Institute for 126 Biotechnology or the MD Anderson Sequencing and Microarray Facility. Variants were called using our previously validated ensemble approach^{12,21}, copy number alterations identified using 127 off-target reads with the CopyWriteR tool³³, and translocation called using FACTERA³⁴. 128 129 Germline polymorphisms were filtered using dbSNP annotation and the EXAC dataset containing 60,706 healthy individuals³⁵. Significantly mutated genes were defined by 130 MutSig2CV³⁶, significant DNA copy number alterations by GISTIC2³⁷, and the clonal 131 representation of mutations by ABSOLUTE³⁸. Mutation and CNA data are publicly viewable 132 133 throuah cBioPortal: https://www.cbioportal.org/study/summary?id=mbn_mdacc_2013. For 134 further details, refer to supplementary methods.

135

136 **RESULTS**

137 Recurrently mutated genes highlight conserved functional hallmarks of B-NHL

138 We used a 380 gene custom targeted sequencing approach to interrogate the genomes of 755 mature B-NHLs, sequencing to an average depth of 599X (Min, 101X; Max, 1785X; Table S1) 139 for a total yield of 2.06 Tbp. Somatic nucleotide variants (SNVs) and small insertions/deletions 140 (InDels) were identified using an ensemble approach that we have previously validated²¹ (Table 141 142 S3) and significantly mutated genes were identified using MutSig2CV (Table S4). Genes that were significantly mutated in the full cohort or in any one of the 4 subtypes with >100 tumors 143 144 (BL, DLBCL, FL, MCL), as well as frequently mutated genes that are targets of AID (Table S5, 145 **Figure 1**), were included in downstream analyses. Mutation distributions were classified using a 146 novel metric that classifies them into hotspot, clustered or diffuse (Figure S2). The residue of 147 mutational hotspots and conserved domains targeted by clustered mutations are shown on figure 1. As a proof of principle, genes such as EZH2 and MYD88 with known mutational 148 hotspots were classified as 'hotspot', and genes such as CREBBP and TCF3 that accumulate 149 mutations within a single domain were classified as 'clustered'. The mutational burden 150 151 calculated from our targeted region significantly correlated with that from the whole exome (Figure S3A) and was significantly higher in DLBCL and other high-grade tumors compared to 152 FL and MCL (Figure 1; Figure S3B). The mutational signatures were also different between 153 154 malignancies, but were predominated by mutations attributable to failure of double-strand break repair by homologous recombination³⁹ (Signature 3; Table S6). 155

156

To identify key hallmarks that are deregulated by somatic mutations, we grouped genes using DAVID functional annotation clustering⁴⁰. BCL6 function is not annotated in gene sets within public databases, but was an obvious feature of the recurrently mutated genes, so this hallmark

was assigned according to literature support. The most frequently perturbed processes were 160 161 chromatin modification and cell signaling, with most of the genes in these categories having been well described in prior reports. Chromatin modifying genes were mutated in 68% of BL, 162 163 66% of DLBCL, 91% of FL and 45% of MCL, and included those that encode proteins that 164 catalyze post-translational modifications of histones (KMT2D, CREBBP, EZH2, EP300, 165 WHSC1, ASHL1L and KMT2A), components of the SWI/SNF chromatin remodeling complex 166 (ARID1A, SMARCA4, BCL7A), linker histores (HIST1H1E, HIST1H1C, HIST1H1B), and the 167 TET2 gene. Genes with a role in signaling included those involved in B-cell receptor (CD79B, 168 ID3, TCF3, RFTN1), toll-like receptor (MYD88), NFkB (TNFAIP3, CARD11, NFKBIE), Notch (NOTCH1, NOTCH2), JAK/STAT (SOCS1, STAT6), PI3K/mTOR (FOX01, ATP6V1B2, 169 APT6AP1) and G-protein (GNA13, GNAI2) signaling. The CD79A and BCL10 genes were also 170 171 mutated at a lower frequency that was not significant by MutSig (Figure S4A-B). Among these, 172 the *RFTN1* gene (Figure S4C) is a novel recurrently mutated gene that was mutated in 7.4% of DLBCL and encodes a lipid raft protein that is critical for B-cell receptor signaling⁴¹. 173

174

175 Other processes that are not as well described as genetic hallmarks of B-NHL included BCL6 176 function and the ubiquitin proteasome system (UPS). Genes associated with BCL6 function encompassed BCL6 itself and its interacting proteins (BCL6, TBL1XR1, BCOR, SPEN), 177 178 regulators of BCL6 activity or expression (MEF2B, IRF8, IRF4), and a critical BCL6 target gene 179 (PRDM1). Recurrent mutations of the NCOR1 and NCOR2 genes that encode BCL6 co-180 repressor proteins were also observed (Figure S4D-E), but were not significant by MutSig2CV. 181 Multiple recurrently mutated chromatin modifying genes have also been implicated in BCL6 function and therefore also contribute to this hallmark, including *CREBBP* and *EZH2*^{42,43}. The 182 recurrently mutated UPS genes included the CDC27 gene, which encodes an E3 ligase for 183 CCND1⁴⁴ that is mutated in 14% of MCL and has not been previously described in the literature. 184

The *TMEM51* gene was also identified as a novel recurrently mutated gene in 9% of BL, though the function of this gene is poorly defined. The cross-sectional analysis of multiple lymphoma subtypes therefore identified conserved hallmarks that are recurrently targeted by somatic mutations in B-NHL.

189

190 Enrichment of functional hallmarks by structural alterations

191 The hybrid capture probes utilized in our design also targeted recurrent breakpoint regions in 192 the immunoglobulin heavy- and light-chain loci, as well as the regions of recurrent breakpoints in or near the BCL2, MYC and BCL6 genes. Translocations were called using a method that 193 detects discordantly mapped reads³⁴ and our prior validation of this approach in cases with 194 matched fluorescence in situ hybridization (FISH) data for MYC showed that it is 100% specific, 195 but only ~40% sensitive for translocation detection¹². In addition, we failed to detect CCND1 196 197 translocations using this approach. However, we did observe a significantly higher fraction of 198 BCL6 translocations (57% [27/47]) partnered to non-immunoglobulin loci (eg. CIITA, RHOH, EIF4A2, ST6GAL1; Table S7) compared to BCL2 (1% [1/114]) and MYC (5% [2/38]) 199 translocations (Figure 2A; Fisher P-value < 0.001). These were more frequent in FL (88% 200 201 [15/17] of BCL6 translocations) as compared to DLBCL (39% [9/23] of BCL6 translocations), 202 presumably because the two immunoglobulin loci in FL are either translocated with the BCL2 gene or functioning in immunoglobulin expression⁴⁵. We also employed off-target reads to 203 detect DNA copy number alterations (CNAs) in a manner akin to low-pass whole genome 204 sequencing, identified significant peaks of copy gain and losses using GISTIC2³⁷ (Figure 2A; 205 206 Figure S5: Table S8-9), and defined the likely targets of these CNAs by integrative analysis of 207 matched gene expression profiling (GEP) data from 290 tumors (Figure 2B-C, Figure S5, Table 208 S10-11). This identified known CNA targets (Figure 2D), including but not limited to deletion of *TNFAIP3* (6q24.2)⁴⁶, *ATM* (11q22.3)⁴⁷, *B2M* (15q15.5)⁴⁸ and *PTEN* (10q23.21)⁴⁹, and copy gain 209

of REL and BCL11A (2p15), and TCF4 (18q23)⁵⁰. In addition, we identified novel targets such 210 211 as deletion of IBTK (6q14.1), UBE3A (11q22.1) and FBXO25 (8p23.3), and copy gain of ATF7 (12q13.13), UCHL5 (1q31.3), and KMT2A (11q23.3). Several CNA peaks, defined as the 212 213 smallest and most statistically significant region, included genes that were significantly mutated 214 (Figure 2E) as well as other genes for which we detected mutations at lower frequencies that 215 were not significant by MutSig (POU2AF1, TP53BP1, FAS, PTEN). Furthermore, for several of 216 these genes (ATM, B2M, BIRC3 and TNFRSF14), deletions were significantly co-associated 217 with mutations, suggesting that deletion and mutation are complementary mechanisms 218 contributing to biallelic inactivation.

219

220 Analyzing targets of translocations and CNAs added to enrichment of functional categories that 221 we observed within recurrently mutated genes, including chromatin modification (BCL11A) and 222 signaling (TCF4, PTEN). This was most prominently observed for genes with a role in apoptosis and the cell cycle (CDKN2A, CDKN2B, FAS, RPL5, DFFB, MDM2, CDK6) and the UPS 223 (CUL4A, FBXO25, IBTK, RNF38, UBAP1, UBE3A, UBQLN1, UCHL5). Recurrently altered UPS 224 225 genes collectively promote or suppress the abundance or activity of proteins with roles in other hallmark characteristics (Figure 3A). For example; SOCS1⁵¹, BIRC3⁵², DTX1^{53,54}, IBTK⁵⁵, 226 TRIM13⁵⁶, TNFAIP3⁵³ and UBE3A⁵³ all inhibit the function of proteins with a role in important B-227 228 cell signaling pathways (Figure 3B), thereby establishing a functional link between genetic alteration of the UPS and deregulation of signaling and adding an additional layer to the 229 230 mechanisms by which B-cell receptor signaling is perturbed in B-NHL. The combined analysis of 231 mutations and structural alterations therefore identified large sets of genes that are targeted by genetic alterations and collectively contribute to hallmark features that are commonly 232 233 deregulated across multiple B-NHL subtypes.

234

235

236 Disease-specific patterns of genetic alterations

237 Some interesting patterns of disease-specificity were obvious for both mutations and structural alterations. We therefore formally tested the over- or under-representation of these events in 238 each of the 4 subtypes with >100 tumors (BL, DLBCL, FL, MCL), compared to all other tumors 239 in the study (Figure 4: Table S12). Using matched GEP data for a subset of cases (Table S1), 240 241 we also tested the association between genetic alterations and molecularly-defined Burkitt's lymphoma subtypes (n=154; Figure S6-7, Table S13), as well as DLBCL cell of origin subtypes 242 243 (n=98; Figure S7, Table S14). These analyses showed that the genetic alterations associated 244 with clinically-defined BL were also associated with molecularly-defined BL. Moreover, genetic 245 alterations that we and others have characterized as being over-represented in ABC-like DLBCL such as CD79B mutation⁵⁷, MYD88 mutation⁵⁸ and TCF4 copy gain⁵⁰ were significantly over-246 247 represented in this analysis also.

248

249 We observed some interesting patterns within hallmark characteristics that differ between 250 subtypes. For example, linker histone mutations were present in germinal center B (GCB)-cell 251 derived malignancies (BL, DLBCL, FL) at variable frequencies, but were largely absent from 252 MCL (Figure S8). In contrast, mutations of genes encoding the H3K36 methyltransferases. 253 WHSC1 (aka MMSET/NSD2) and ASH1L, were frequent in MCL and largely absent from GCB-254 derived malignancies. We also noted that the SWI/SNF complex was perturbed in different ways in different diseases (Figure 5). Specifically, mutations of the SMARCA4 (aka. BRG1) 255 256 component of the ATPase module were significantly enriched in BL (24%) compared to other 257 subtypes (4%, Q-value<0.001), while mutations of the BCL7A component of the ATPase 258 module were significantly enriched in FL (11%) compared to other subtypes (4%, Q-

259 value=0.007). In contrast, mutations of ARID1A were frequent in both BL (19%) and FL (15%), 260 and DNA copy number gains of BCL11A were frequent in both DLBCL (28%) and FL (22%). The SWI/SNF complex is therefore a target of recurrent genetic alterations, as previously 261 262 suggested⁵⁹, but the manner in which this complex is perturbed varies between B-NHL subtypes 263 (Figure 5). Similar disease-specific patterns were also observed for signaling genes; for example, TCF3 and ID3 have important functions in normal germinal center B-cells⁶⁰, but 264 265 mutations of these genes are specifically enriched within BL and are rarely found in the other 266 GCB-derived malignancies, DLBCL and FL. Similarly, the ATP6AP1 and ATP6V1B2 genes that function in mTOR signaling^{61,62} are specifically mutated in FL, and the *DUSP*2 gene which 267 inactivates ERK1/2⁶³ and STAT3⁶⁴ is specifically mutated in DLBCL. The disease-specific 268 269 patterns of genetic alterations therefore reveal subtle but important differences in how each 270 subtype of B-NHL perturbs hallmark features.

271

272 <u>Pathognomonic sets of co-associated genomic alterations in B-NHL subtypes</u>

273 We next defined how each genetic alteration co-associated with or mutually-excluded other 274 genetic alterations by pairwise assessments using false-discovery rate (FDR)-corrected Fisher's 275 tests (Table S15). A matrix of the transformed FDR Q-values (-logQ) was used for unsupervised 276 hierarchical clustering to identify clusters of co-associated genetic alterations. Together with 277 patterns of disease-specificity, unsupervised clustering revealed clear groupings of coassociated events for BL, DLBCL, FL and MCL (Figure 4). We identified a single cluster that 278 was specifically enriched in DLBCL, included co-associated genetic alterations that were over-279 represented in the ABC-like, and overlapped with the previously described C5/MCD clusters^{3,4}. 280 281 We also identified a cluster consisting of TP53 mutations and multiple CNAs similar to the C2 282 subtype reported in DLBCL, but which was enriched in both FL and DLBCL. A cluster with 283 features similar to the C3/EZB DLBCL clusters was also observed, but was specifically enriched

in FL. The remaining two previously reported DLBCL clusters (C1/N2 and C4) were not observed in this analysis, which may be a result of the different clustering strategies used and/or the lower number of DLBCL tumors in this study compared to other prior DLBCL-focused efforts^{3,4}. We therefore focused our subsequent description on BL, FL and MCL.

288

The core set of co-associated genetic alterations in BL were MYC translocation and mutation, 289 and mutations of SMARCA4, CCND3 and ID3. Mutations of GNAI2, GNA13, FOXO1, TCF3, 290 ARID1A and TMEM51 were also clustered with this core set, but were present at lower 291 292 frequencies. Mutations of *TP53* and copy gain of 1q were frequent in BL, but did not cluster 293 together with other BL-associated genetic alterations. The core set of genetic alterations in FL 294 were BCL2 translocations and mutations, and mutations of KMT2D, CREBBP and EZH2, in line with prior observations^{16,21}. Copy loss of 10q23.31 encompassing the FAS and PTEN genes, 295 296 and mutations EEF1A1, TNFRSF14, IRF8, BCL7A, ATP6V1B2 and ATP6AP1 were present at lower frequencies and clustered with this core set. The MCL cluster included mutations and 297 deletions of ATM and BIRC3, as well as frequent deletions of 9p21.32 (CDKN2A and CDKN2B), 298 9q21.3 (UBQLN1), 13q14.2 (miR-15a/16 and TRIM13), 13q34 (CUL4A and ING1), and 1p21 299 (RPL5). Mutation of BCOR, UBR5, SP140, CCND1 and WHSC1 were also significantly over-300 represented in MCL compared to other subtypes, and were associated with this cluster. These 301 302 data show that different subtypes of B-NHL are defined by characteristic sets of co-associated 303 genetic alterations that affect multiple hallmarks.

304

305 <u>Combinations of clonal genetic alterations define B-NHL subtypes</u>

306 Our data have revealed statistical enrichment of individual genetic alterations in subtypes of B-307 NHL, and pairwise relationships between different genetic alterations that define clusters of

308 subtype-specific events. However, individual genetic alterations from disease-specific clusters 309 are also observed at variable frequencies in other B-NHL subtypes (Figure 6A). We therefore investigated whether the combination of multiple genetic alterations from each cluster, rather 310 311 than the presence or absence of a single alteration, were pathognomonic. By enumerating the 312 number of genetic alterations from each disease-specific cluster in each tumor, we found that 313 this was indeed the case. Specifically over half of all BL, FL and MCL tumors possessed ≥3 314 genetic alterations defined by their respective subtype-specific clusters (Figure 6). These rates were significantly higher than those observed in other diseases (Fisher P <0.001 for all 315 comparisons). For example, DLBCL and FL share many of the same recurrently mutated genes, 316 particularly when considering the C3/EZB subtype of DLBCL^{3,4}. Thus, one or more FL cluster 317 318 alterations are found in 93% of FL tumors, but also in 54% of DLBCL tumors. However, FL 319 tumors have a significantly higher rate of accumulation of these mutations, with 68% of FL 320 tumors bearing ≥ 3 of the FL cluster alterations but only 18% of DLBCL tumors bearing ≥ 3 of 321 these genetic alterations (Fisher P < 0.001). This pattern is also conserved for the BL and MCL 322 clusters, for which the rate of acquiring ≥ 3 of the cluster alterations was significantly higher in BL 323 or MCL compared to other subtypes of B-NHL, respectively. Thus, B-NHL subtypes are defined 324 by the acquisition of multiple genetic alterations from subtype-associated clusters.

325

The co-association of multiple mutations may be suggestive of a clonal structure in which early driver mutations are clonal and later driver mutations are present in sub-clones. We therefore utilized ABSOLUTE (Table S16-18) to determine whether co-associated genetic alterations are present at different clonal fractions, and could therefore be phased to create clonal hierarchies. This analysis failed for a small subset of cases and could not be performed for X-linked genes or translocations. However, it clearly revealed the majority of co-associated genetic alterations were present at cancer cell fractions (CCF) >0.9, which is indicative that each mutation is clonally represented in every cancer cell at the time of sampling. These data suggest that combinations of mutations may therefore be required for effective expansion of lymphoma cells, such that common precursor cells (CPCs) are not detectable within the clonal structure of the clinically-detected tumor. These data therefore support the premise of epistatic interactions between co-occurring genetic alterations in B-NHL.

338

339 **DISCUSSION**

340 By performing cross-sectional genomic profiling of a large cohort of tumors, we have defined 341 genes and functional hallmarks that are recurrently targeted by genetic alterations and showed 342 that combinations of genetic alterations are disease-defining features of B-NHL subtypes. Some 343 of the functional hallmarks that we identified have been previously appreciated in other 344 diseases, with a few exceptions. For example, the mutation of genes with roles in chromatin modification are known to be a hallmark of FL⁶⁵ and we observed that over 90% of FLs 345 346 possessed mutations in one or more of the genes in this category. However, these mutations were also observed in two thirds of BL and DLBCL tumors and nearly half of MCLs. There are 347 subtype-specific patterns of chromatin modifying gene alterations, such as those that we 348 349 described for H3K36 methylation in MCL and the unique patterns of SWI/SNF mutations across 350 GCB-derived B-NHLs. But we suggest that the genetic deregulation of chromatin modification 351 should be considered a general hallmark of B-NHL. In addition, we suggest that the 352 deregulation of BCL6 function and perturbation of the ubiquitin proteasome system are 353 hallmarks of B-NHL that require further investigation. We have highlighted some of the known 354 substrates of recurrently altered UPS genes from the literature, which shows the potential for 355 these genetic alterations to contribute to aberrant B-cell receptor signaling and proliferation. 356 However, many of the genes within these categories have not been functionally studied in the

context of B-cell lymphoma, which represents a significant gap in our understanding of diseaseetiology.

359

The role of epistatic interactions between co-occurring genetic alterations is also an emerging 360 field that requires further investigation. These interactions are not uncommon in cancer⁶⁶, but 361 362 our data show that they are pervasive and disease-defining features of the B-NHL genetic 363 landscape. Epistasis between co-associated genetic alterations identified in this study requires 364 formal validation in cell line and/or animal models. However, there are many instances in which 365 co-occurring genetic alterations that we observed have already been shown to cooperate in 366 lymphomagenesis. In addition to the aforementioned example of MYD88 and CD79B mutations, 367 transgenic mouse models of Ezh2 activating mutations or conditional deletion of Crebbp or *Kmt2d* have shown that these events are not alone sufficient for lymphomagenesis^{42,67-71}. We 368 369 and others have observed a co-association between the mutation of these genes and BCL2 370 translocations^{16,21}, and the addition of a *Bcl*2 transgene to these murine models indeed 371 promoted lymphoma at a significantly higher rate than that observed with the Bcl2 transgene alone^{42,67-71}. These genetic alterations are therefore significantly more lymphomagenic in 372 373 combination than they are alone, which provides proof of principal that an epistatic relationship 374 exists between these co-occurring genetic alterations. Future studies focusing on other co-375 occurring mutations, such as MYC translocation and SMARCA4 mutation in BL, CREBBP and KMT2D mutation in FL, TCF4 copy gain and MYD88 mutation in DLBCL, and ATM mutation and 376 377 RPL5 deletion in MCL, should therefore be performed to further explore these concepts and 378 define their underlying functional relationship. We suggest that combinations of genetic 379 alterations are likely to more accurately recapitulate the biology of B-NHL than single gene 380 models, and may reveal contextually different functional roles of genetic alterations depending on the co-occurring events. 381

382

In conclusion, we have provided a framework of functional hallmarks and co-occurring genetic alterations that are enriched within B-NHL subtypes. These genetic alterations likely represent epistatic interactions that underpin the biology of these tumors, and represent an opportunity for better understanding lymphoma etiology so that we can identify novel rational approaches for therapeutic targeting of the underlying biology.

388

389 ACKNOWLEDGEMENTS

This research was supported by NCI R01CA201380 (MRG), the Nebraska Department of Health and Human Services (LB506 2016-17; MRG), the Jaime Erin Follicular Lymphoma Research Consortium (MRG and SSN), the Futcher Foundation (LN and MRG), the Schweitzer Family Fund (JRW, RED, MRG), a Leukemia and Lymphoma Society Fellow Award (HY), and NCI cancer center support grants to the University of Texas MD Anderson Cancer Center (P30 CA016672) and the Fred & Pamela Buffet Cancer Center (P30 CA036727).

396

397 AUTHOR CONTRIBUTIONS

MCJM and ST performed experiments, analyzed data and wrote the manuscript. AB analyzed data. AB, TBH, HY, QD, DM, KH, NJ, JS, and SG performed experiments. AA, LS, MD, CC, JT, DP, KMV, MAL, ARS, BJC, RB, SSN, LN, RED, JW, SP, MKG, DS, JI, TG, SR, and AM provided samples and/or clinical data. MRG conceived and supervised the study, performed experiments, analyzed the data and wrote the manuscript. All authors reviewed and approved the manuscript.

404

405 DISCLOSURES OF CONFLICTS OF INTEREST

406 The authors have no conflicts of interest related to this work.

407

408

409 **REFERENCES**

- Swerdlow, S. H. *et al.* The 2016 revision of the World Health Organization classification
 of lymphoid neoplasms. *Blood* **127**, 2375-2390, doi:10.1182/blood-2016-01-643569
 (2016).
- 413 2 Årmitage, J. O., Gascoyne, R. D., Lunning, M. A. & Cavalli, F. Non-Hodgkin lymphoma. 414 *Lancet* **390**, 298-310, doi:10.1016/S0140-6736(16)32407-2 (2017).
- Chapuy, B. *et al.* Molecular subtypes of diffuse large B cell lymphoma are associated
 with distinct pathogenic mechanisms and outcomes. *Nature medicine* 24, 679-690,
 doi:10.1038/s41591-018-0016-8 (2018).
- 418 4 Schmitz, R. *et al.* Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *The* 419 *New England journal of medicine* **378**, 1396-1407, doi:10.1056/NEJMoa1801445 (2018).
- 420
 5
 Reddy, Å. *et al.* Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. *Cell*

 421
 171, 481-494 e415, doi:10.1016/j.cell.2017.09.027 (2017).
- 422 6 Bea, S. *et al.* Landscape of somatic mutations and clonal evolution in mantle cell 423 lymphoma. *Proceedings of the National Academy of Sciences of the United States of* 424 *America* **110**, 18250-18255, doi:10.1073/pnas.1314608110 (2013).
- Zhang, J. *et al.* The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. *Blood* 123, 2988-2996, doi:10.1182/blood-2013-07-517177 (2014).
- 428 8 Wang, J. Q. *et al.* Synergistic cooperation and crosstalk between MYD88L265P and 429 mutations that dysregulate CD79B and surface IgM. *The Journal of experimental* 430 *medicine* **214**, 2759-2776, doi:10.1084/jem.20161454 (2017).
- 431 9 Lenz, G. *et al.* Stromal gene signatures in large-B-cell lymphomas. *The New England* 432 *journal of medicine* **359**, 2313-2323, doi:10.1056/NEJMoa0802885 (2008).
- Dave, S. S. *et al.* Molecular diagnosis of Burkitt's lymphoma. *The New England journal of medicine* **354**, 2431-2442, doi:10.1056/NEJMoa055759 (2006).
- Iqbal, J. *et al.* Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct
 subgroup with poor prognosis. *Blood* **119**, 4939-4948, doi:10.1182/blood-2011-07370122 (2012).
- Bouska, A. *et al.* Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature:
 Genomic features and Potential Therapeutic Targets. *Blood*, doi:10.1182/blood-2017-02 767335 (2017).
- Khodadoust, M. S. *et al.* Antigen presentation profiling reveals recognition of lymphoma
 immunoglobulin neoantigens. *Nature* 543, 723-727, doi:10.1038/nature21433 (2017).
- 44314Schmitz, R. *et al.* Burkitt lymphoma pathogenesis and therapeutic targets from structural
and functional genomics. *Nature* **490**, 116-120, doi:10.1038/nature11378 (2012).
- Love, C. *et al.* The genetic landscape of mutations in Burkitt lymphoma. *Nature genetics*446
 44, 1321-1325, doi:10.1038/ng.2468 (2012).

- 447 16 Morin, R. D. *et al.* Frequent mutation of histone-modifying genes in non-Hodgkin 448 lymphoma. *Nature* **476**, 298-303, doi:10.1038/nature10351 (2011).
- Morin, R. D. *et al.* Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. *Blood* **122**, 1256-1265, doi:10.1182/blood-2013-02-451
 483727 (2013).
- 452 18 Pasqualucci, L. *et al.* Analysis of the coding genome of diffuse large B-cell lymphoma.
 453 *Nature genetics* 43, 830-837, doi:10.1038/ng.892 (2011).
- 454 19 Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell 455 lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy Sciences of States America 456 the United of 109, 3879-3884, of doi:10.1073/pnas.1121343109 (2012). 457
- 458 20 Green, M. R. *et al.* Hierarchy in somatic mutations arising during genomic evolution and 459 progression of follicular lymphoma. *Blood* **121**, 1604-1611, doi:10.1182/blood-2012-09-460 457283 (2013).
- 461 21 Green, M. R. *et al.* Mutations in early follicular lymphoma progenitors are associated with 462 suppressed antigen presentation. *Proceedings of the National Academy of Sciences of* 463 *the United States of America* **112**, E1116-1125, doi:10.1073/pnas.1501199112 (2015).
- 464 22 Okosun, J. *et al.* Integrated genomic analysis identifies recurrent mutations and
 465 evolution patterns driving the initiation and progression of follicular lymphoma. *Nature* 466 *genetics* 46, 176-181, doi:10.1038/ng.2856 (2014).
- Pasqualucci, L. *et al.* Genetics of follicular lymphoma transformation. *Cell reports* 6, 130140, doi:10.1016/j.celrep.2013.12.027 (2014).
- Landau, D. A. *et al.* Evolution and impact of subclonal mutations in chronic lymphocytic
 leukemia. *Cell* 152, 714-726, doi:10.1016/j.cell.2013.01.019 (2013).
- Puente, X. S. *et al.* Whole-genome sequencing identifies recurrent mutations in chronic
 lymphocytic leukaemia. *Nature* 475, 101-105, doi:10.1038/nature10113 (2011).
- 473 26 Wang, L. *et al.* SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
 474 *The New England journal of medicine* **365**, 2497-2506, doi:10.1056/NEJMoa1109016
 475 (2011).
- 476 27 Kiel, M. J. *et al.* Whole-genome sequencing identifies recurrent somatic NOTCH2
 477 mutations in splenic marginal zone lymphoma. *The Journal of experimental medicine*478 209, 1553-1565, doi:10.1084/jem.20120910 (2012).
- Rossi, D. *et al.* The coding genome of splenic marginal zone lymphoma: activation of
 NOTCH2 and other pathways regulating marginal zone development. *The Journal of experimental medicine* **209**, 1537-1551, doi:10.1084/jem.20120904 (2012).
- 482 29 Chapman, M. A. *et al.* Initial genome sequencing and analysis of multiple myeloma. 483 *Nature* **471**, 467-472, doi:10.1038/nature09837 (2011).
- 48430Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia.485The New England journal of medicine **367**, 826-833, doi:10.1056/NEJMoa1200710486(2012).
- 487 31 Gunawardana, J. *et al.* Recurrent somatic mutations of PTPN1 in primary mediastinal B 488 cell lymphoma and Hodgkin lymphoma. *Nature genetics* **46**, 329-335, 489 doi:10.1038/ng.2900 (2014).
- Vater, I. *et al.* The mutational pattern of primary lymphoma of the central nervous system
 determined by whole-exome sequencing. *Leukemia* 29, 677-685,
 doi:10.1038/leu.2014.264 (2015).
- 49333Kuilman, T. et al. CopywriteR: DNA copy number detection from off-target sequence494data. Genome biology 16, 49, doi:10.1186/s13059-015-0617-1 (2015).
- 495 34 Newman, A. M. *et al.* FACTERA: a practical method for the discovery of genomic
 496 rearrangements at breakpoint resolution. *Bioinformatics* 30, 3390-3393,
 497 doi:10.1093/bioinformatics/btu549 (2014).

- 498 35 Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285-291, doi:10.1038/nature19057 (2016).
- Lawrence, M. S. *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* **499**, 214-218, doi:10.1038/nature12213 (2013).
- 502 37 Mermel, C. H. *et al.* GISTIC2.0 facilitates sensitive and confident localization of the 503 targets of focal somatic copy-number alteration in human cancers. *Genome biology* **12**, 504 R41, doi:10.1186/gb-2011-12-4-r41 (2011).
- 505 38 Carter, S. L. *et al.* Absolute quantification of somatic DNA alterations in human cancer. 506 *Nature biotechnology* **30**, 413-421, doi:10.1038/nbt.2203 (2012).
- Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415-421, doi:10.1038/nature12477 (2013).
- Huang, D. W. *et al.* DAVID Bioinformatics Resources: expanded annotation database
 and novel algorithms to better extract biology from large gene lists. *Nucleic acids research* 35, W169-175, doi:10.1093/nar/gkm415 (2007).
- Saeki, K., Miura, Y., Aki, D., Kurosaki, T. & Yoshimura, A. The B cell-specific major raft
 protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. *EMBO J* 22, 3015-3026, doi:10.1093/emboj/cdg293 (2003).
- 515 42 Jiang, Y. *et al.* CREBBP Inactivation Promotes the Development of HDAC3-Dependent 516 Lymphomas. *Cancer discovery* **7**, 38-53, doi:10.1158/2159-8290.CD-16-0975 (2017).
- 51743Beguelin, W. et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to518Repress Bivalent Promoters, Mediate Germinal Center Formation and519Lymphomagenesis. Cancer cell **30**, 197-213, doi:10.1016/j.ccell.2016.07.006 (2016).
- 520 44 Pawar, S. A. et al. C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation 521 via induction of CDC27/APC3 expression. Proceedings of the National Academy of 522 Sciences of the United States of America 107. 9210-9215, 523 doi:10.1073/pnas.0913813107 (2010).
- Akasaka, T., Lossos, I. S. & Levy, R. BCL6 gene translocation in follicular lymphoma: a
 harbinger of eventual transformation to diffuse aggressive lymphoma. *Blood* 102, 1443 1448, doi:10.1182/blood-2002-08-2482 (2003).
- 46 Kato, M. *et al.* Frequent inactivation of A20 in B-cell lymphomas. *Nature* **459**, 712-716, doi:10.1038/nature07969 (2009).
- Greiner, T. C. *et al.* Mutation and genomic deletion status of ataxia telangiectasia
 mutated (ATM) and p53 confer specific gene expression profiles in mantle cell
 lymphoma. *Proceedings of the National Academy of Sciences of the United States of America* 103, 2352-2357, doi:10.1073/pnas.0510441103 (2006).
- 533 48 Challa-Malladi, M. *et al.* Combined genetic inactivation of beta2-Microglobulin and CD58
 534 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
 535 Cancer cell 20, 728-740, doi:10.1016/j.ccr.2011.11.006 (2011).
- 49 536 Pfeifer, M. et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proceedings of the National Academy of 537 110. 538 Sciences of the United States of America 12420-12425, doi:10.1073/pnas.1305656110 (2013). 539
- Jain N, H. K., Tadros S, Fiskus W, Havranek O, Ma M, Bouska A, Heavican T, Kumar D,
 Deng Q, Moore D, Pak C, Liu C, Gentles A, Hartmann E, Kridel R, Ekstrom-Smedby K,
 Juliusson G, Rosenquist R, Gascoyne R, Rosenwald A, Giancotti F, Neelapu S, Westin
 J, Vose J, Lunning M, Greiner T, Rodig S, Iqbal J, Alizadeh A, Davis RE, Bhalla K,
 Green M. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin
 expression in the activated B-cell subtype of diffuse large B-cell lymphoma. *Sci. Transl. Med.* In Press (2019).

- 51 Ingley, E. *et al.* Csk-binding protein mediates sequential enzymatic down-regulation and
 degradation of Lyn in erythropoietin-stimulated cells. *The Journal of biological chemistry* 549 281, 31920-31929, doi:10.1074/jbc.M602637200 (2006).
- 550 52 Hu, S., Alcivar, A., Qu, L., Tang, J. & Yang, X. CIAP2 inhibits anigen receptor signaling 551 by targeting Bcl10 for degredation. *Cell cycle* **5**, 1438-1442, doi:10.4161/cc.5.13.2866 552 (2006).
- 553 53 Compagno, M. *et al.* Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. *Nature* **459**, 717-721, doi:10.1038/nature07968 (2009).
- Liu, W. H. & Lai, M. Z. Deltex regulates T-cell activation by targeted degradation of active MEKK1. *Molecular and cellular biology* **25**, 1367-1378, doi:10.1128/MCB.25.4.1367-1378.2005 (2005).
- 558 55 Liu, W. *et al.* Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. 559 *Nature immunology* **2**, 939-946, doi:10.1038/ni1001-939 (2001).
- 560 Joo, H. M. et al. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via 56 degradation and MDM2. Eur J 561 of AKT Cell Biol **90**, 420-431. doi:10.1016/j.ejcb.2010.12.001 (2011). 562
- 563 57 Davis, R. E. *et al.* Chronic active B-cell-receptor signalling in diffuse large B-cell 564 lymphoma. *Nature* **463**, 88-92, doi:10.1038/nature08638 (2010).
- 565
 58
 Ngo, V. N. *et al.* Oncogenically active MYD88 mutations in human lymphoma. *Nature*

 566
 470, 115-119, doi:10.1038/nature09671 (2011).
- 567 59 Krysiak, K. *et al.* Recurrent somatic mutations affecting B-cell receptor signaling pathway 568 genes in follicular lymphoma. *Blood* **129**, 473-483, doi:10.1182/blood-2016-07-729954 569 (2017).
- 570 60 Gloury, R. *et al.* Dynamic changes in Id3 and E-protein activity orchestrate germinal 571 center and plasma cell development. *The Journal of experimental medicine* **213**, 1095-572 1111, doi:10.1084/jem.20152003 (2016).
- 573 61 Okosun, J. *et al.* Recurrent mTORC1-activating RRAGC mutations in follicular 574 Iymphoma. *Nature genetics* **48**, 183-188, doi:10.1038/ng.3473 (2016).
- Wang, F. *et al.* Follicular lymphoma-associated mutations in vacuolar ATPase
 ATP6V1B2 activate autophagic flux and mTOR. *The Journal of clinical investigation* **130**,
 1626-1640, doi:10.1172/JCI98288 (2019).
- Hu, J. *et al.* MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation
 in pancreatic ductal adenocarcinoma. *Cell Death Dis* 9, 807, doi:10.1038/s41419-0180839-8 (2018).
- 58164Lu, D. *et al.* The phosphatase DUSP2 controls the activity of the transcription activator582STAT3 and regulates TH17 differentiation. Nature immunology 16, 1263-1273,583doi:10.1038/ni.3278 (2015).
- 58465Green, M. R. Chromatin modifying gene mutations in follicular lymphoma. Blood 131,585595-604, doi:10.1182/blood-2017-08-737361 (2018).
- 58666Ashworth, A., Lord, C. J. & Reis-Filho, J. S. Genetic interactions in cancer progression587and treatment. *Cell* **145**, 30-38, doi:10.1016/j.cell.2011.03.020 (2011).
- 588 67 Beguelin, W. *et al.* EZH2 is required for germinal center formation and somatic EZH2 589 mutations promote lymphoid transformation. *Cancer cell* **23**, 677-692, 590 doi:10.1016/j.ccr.2013.04.011 (2013).
- 591 68 Garcia-Ramirez, I. *et al.* Crebbp loss cooperates with Bcl2 over-expression to promote 592 lymphoma in mice. *Blood* **129**, 2645-2656, doi:10.1182/blood-2016-08-733469 (2017).
- 593 69 Zhang, J. *et al.* The Crebbp Acetyltransferase is a Haploinsufficient Tumor Suppressor in 594 B Cell Lymphoma. *Cancer discovery*, doi:10.1158/2159-8290.CD-16-1417 (2017).
- 59570Zhang, J. et al. Disruption of KMT2D perturbs germinal center B cell development and596promotes lymphomagenesis. Nature medicine 21, 1190-1198, doi:10.1038/nm.3940597(2015).

Ortega-Molina, A. *et al.* The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. *Nature medicine* 21, 1199-1208, doi:10.1038/nm.3943 (2015).

601

602

603

604

605 **FIGURE LEGENDS**

Figure 1: Recurrently mutated genes in B-NHL subtypes. An oncoplot shows significantly mutated genes across our cohort of 755 B-NHL tumors, arranged according to functional category and frequency. The mutational burden and distribution of mutation types for each case are shown at the top. Amino acid residues for mutational hotspots and/or domains targeted by clustered mutations are shown on the right.

611

612 Figure 2: Structural alterations in B-NHL subtypes. A) A circos plot shows translocations of 613 the MYC (purple), BCL2 (orange) and BCL6 (green) genes, and GISTIC tracks of DNA copy 614 number gains (red) and losses (blue). **B-C)** Volcano plots of integrative analysis results showing 615 the changes in gene expression of genes within peaks of DNA copy number gain (B) or loss (C). 616 The shaded region in B marks genes with significantly increased expression in tumors with 617 increased copy number compared to those without; the converse is true for the shaded region in 618 C. D) An oncoplot with DNA copy number losses and gains ranked according to their frequency 619 shows the distribution of structural alterations across tumors. E) Oncoplots show the overlap of structural alterations and mutations that target the same genes. P-values are derived from a 620 621 Fisher's exact test (ns, not significant).

- 622
- 623
- 624
- 625

626

Figure 3: Genetic alterations of the ubiquitin proteasome system (UPS) and potential interplay with BCR signaling. A) A graphical illustration of UPS gene genetic alterations (mutations, teal; deletions, blue; copy gain, red) and literature supported targets of the UPS genes. The function of UPS gene targets is categorized according to the hallmarks shown in figure 1. B) A schematic of the different layers of genetic alterations (mutations, teal; deletions, blue; copy gain, red) affecting signaling pathways in B-NHL. UPS genes are highlighted with a yellow halo.

634

Figure 4: Subtype-specific clusters of co-occurring genetic alterations. The frequency (bar graph) and over/under-representation (blue to yellow scale) of mutations and structural alterations is shown on the left for BL, DLBCL, FL and MCL. Over/under-representation in molecular Burkitt and cell of origin molecular subtypes is shown for each alteration at the bottom. The correlation matrix of co-associated (green) and mutually-exclusive (purple) relationships was clustered and identified groups of co-occurring genetic alterations that were predominantly over-represented in a single B-NHL subtype.

642

643

- 644
- 645
- 646
- 647


648

649 Figure 5: Subtype-specific patterns of SWI/SNF complex mutations. A) An oncoplot shows 650 the frequency of genetic alterations in genes that encode components of the SWI/SNF complex. 651 B) A schematic of the SWI/SNF complex shows recurrently mutated genes, ARID1A, 652 SMARCA4 and BCL7A, and the BCL11A gene that is targeted by 2p15 DNA copy number 653 gains. C-E) Lollipop plots show the distribution of mutations in the SWI/SNF components 654 ARID1A (C), SMARCA4 (D), and BCL7A (E). F) A heatplot shows the location of chromosome 655 2p DNA copy number gains (red) in all tumors (rows) with 2p15 copy gain (n=92, copy number > 2.2) ordered from highest DNA copy number (top) to lowest (bottom). The BCL11A gene is in 656 657 the peak focal copy gain.

658

659 Figure 6: Cumulative burden of clonal co-occurring mutations. A) A bar plot shows the 660 frequency of tumors with genetic alterations from each subtype-defining cluster, grouped by the number of co-occurring alterations observed per tumor. The frequency of tumors with 3 or more 661 genetic alterations per tumor is significantly higher in the subtype for which each cluster is 662 663 named (***Fisher P-value < 0.001). B-D) An oncoplot, colored by cancer cell fraction (CCF) from ABSOLUTE, shows the representation and clonality of BL cluster (B), FL cluster (C) and MCL 664 665 cluster (D) mutations across the dataset. The rate of co-occurrence of multiple genetic alterations in a single tumor (columns) is observably higher in the subtypes for which the 666

- clusters are named, and the co-occurring genetics are most often clonal (CCF > 0.9). BL, Burkitt
- 668 Lymphoma. HG, other high-grade lymphoma (DHL/THL, HGBL-NOS). DLBCL, diffuse large B-
- 669 cell lymphoma. FL, follicular lymphoma. MCL, mantle cell lymphoma. LG, other low-grade
- 670 lymphoma (CLL/SLL, MZL).







Figure 3






Figure 5




Figure 6

